NEW YORK, Aug. 8, 2017 /PRNewswire/ -- WeissLaw LLP is
investigating possible breaches of fiduciary duty and other
violations of law by the Board of Directors of NxStage Medical,
Inc. (NASDAQ: NXTM) ("NXTM" or the "Company") in connection with
the proposed acquisition of the Company by Fresenius Medical Care
("Fresenius"). On August 7,
2017, the Company announced a definitive agreement for
Fresenius to acquire all outstanding shares of NXTM in a
transaction valued at approximately $2.0
billion. Under the terms of the agreement, the
Company's shareholders will receive $30.00 in cash for each NXTM share they own.
WeissLaw is investigating whether NXTM's Board acted to maximize
shareholder value prior to entering into the agreement.
Notably, at least one analyst set a target price of $33.00 per share. Additionally, NXTM shares
traded at $30.80, or $0.80 above the offer price, as recently as
May. Further, the Company recently announced positive
financial results. In a separate press release issued on
August 7, 2017, NXTM reported total
revenue of $96.2 million,
representing an annual increase of 4% or $4.0 million, when compared to the $92.2 million reported in the same period of the
previous year.
Given these facts, WeissLaw is investigating whether NXTM's
Board acted in the best interests of its public shareholders to
maximize shareholder value prior to entering into the
agreement. If you own NXTM shares and would like more
information about your rights or our investigation, or if you have
information to share with us, please contact Mark Smilow by telephone at
(888) 593-4771 or by email at
stockinfo@weisslawllp.com.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com or fill out the form
on our website,
http://www.weisslawllp.com/nxstage-medical-inc/
View original
content:http://www.prnewswire.com/news-releases/weisslaw-llp-nxstage-medical-inc-acquisition-may-not-be-in-the-best-interests-of-nxtm-shareholders-300501363.html
SOURCE WeissLaw LLP